Discounted Cash Flow
Rxsight, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $14.7m | $27.6m | $947.0k | 187.9% | $0.91 |
| 2021 | $22.6m (53.9%) | $-48.7m (-276.6%) | $1.2m (30.8%) | -215.5% (-214.7%) | $-3.57 (-492.3%) |
| 2022 | $49.0m (116.9%) | $-66.8m (-37.1%) | $1.9m (52.4%) | -136.2% (36.8%) | $-2.41 (32.5%) |
| 2023 | $89.1m (81.8%) | $-48.6m (27.2%) | $1.9m (2.4%) | -54.6% (59.9%) | $-1.41 (41.5%) |
| 2024 | $139.9m (57.1%) | $-27.5m (43.5%) | $1.6m (-16.8%) | -19.6% (64.0%) | $-0.71 (49.6%) |
| 2025 | $134.5m (-3.9%) | $-38.9m (-41.8%) | $2.2m (37.1%) | -29.0% (-47.6%) | $-0.95 (-33.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.